Press Release Dec 01 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Ivabradine Tablets in two dosages. The approval allows Zydus to manufacture the drug at its facility in Ahmedabad SEZ, India, which is indicated for heart failure treatment. Zydus was among the first applicants for this drug and may qualify for a period of generic exclusivity. The press release aims to inform investors and the exchange members about this significant regulatory milestone.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 10 2023
- Press Release Nov 07 2023
- Press Release Nov 06 2023
- Press Release Nov 03 2023
- Press Release Nov 02 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Dec 06 2023
- Zydus Lifesciences Limited Press Release Dec 11 2023
- Press Release Dec 14 2023
- Press Release Dec 15 2023
- Press Release Dec 16 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences